The high expression of both CD44 and CD90 was associated with significantly reduced relapse-free survival in patients with non-small cell lung cancer [37], suggesting that CD44+CD90+ cells may have stronger CSC properties. This evidence concerns the gene THY1 and non-small cell lung carcinoma.